HULUWA(SH:605199) Xin Lang Cai Jing·2025-12-29 03:23Core Viewpoint - Hainan Huluwa Pharmaceutical Group Co., Ltd. is under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure laws, leading to potential civil compensation claims from affected investors [1][2][6]. Group 1: Company Announcement - On March 15, 2025, Huluwa announced that it received a notice of investigation from the CSRC due to alleged information disclosure violations by the company and its chairman, Liu Jingping [1][6]. - The CSRC previously issued an administrative regulatory decision on the same day, identifying inaccuracies in the financial disclosures of the 2023 annual report, including revenue and profit figures [6]. Group 2: Financial Data Correction - On April 29, 2025, Huluwa released a correction notice regarding prior accounting errors affecting the financial data in the 2023 annual report and the 2024 semi-annual, first quarter, and third quarter reports [1][6]. Group 3: Investor Compensation - Investors who purchased Huluwa's stocks or bonds between April 27, 2024, and March 14, 2025, and sold or continued to hold them after March 15, 2025, may register for compensation claims [2][6]. - The compensation scope includes investment differences, commissions, stamp duties, and interest losses due to the alleged fraudulent activities [2][6]. Group 4: Legal Proceedings - Investors are advised that while they can initiate lawsuits without an administrative penalty decision, the lack of such a decision may increase the risk of losing the case [3][7]. - The progress of civil compensation lawsuits may be affected by the company's potential delisting or bankruptcy proceedings [8].